As interest rates fall, business development companies', or BDCs, return on equity will likely be pressured. Oppenheimer ...

Yet, MAD still dominates countries’ nuclear thinking. Opinion: Our nuclear weapons are much more powerful than Oppenheimer's atomic bomb At a time of profound global changes and instability ...

Oppenheimer lowered the firm’s price target on Acrivon Therapeutics (ACRV) to $10 from $18 and keeps an Outperform rating on the shares ...

Oppenheimer said on Wednesday it no longer expects growth in U.S. investment banking revenue this year and slashed its ...

Christopher Nolan ’s Oppenheimer was that rare movie that was both a box office hit and a serious award winner. It also had ...

Oppenheimer analyst Steven Lichtman maintained a Buy rating on Alcon (ALC – Research Report) today and set a price target of $105.00. The ...

Oppenheimer called the expected M&A rebound under the Trump administration “delayed or cancelled” and downgraded to "perform" ...

A popular theory frequently utilized by technical analysts suggests U.S. stocks could be headed for one last leg higher over ...

(JTA) — Friday is not just “Barbie” release day — moviegoers are also planning to fill theaters across the United States to see Christopher Nolan’s “Oppenheimer” biopic. Many hope it ...

Christopher Nolan doesn't need an image to maintain; from Following (1998) to Oppenheimer (2023), fans know what's in store ...

Oppenheimer maintained its Outperform rating on AppLovin (NASDAQ:APP) while highlighting key points for the company from the annual retail and e-commerce industry conference, Shoptalk 2025.

Oppenheimer upgraded The Mosaic Company (NYSE:MOS) to Outperform from Perform and set a price target of $33 given the fertilizer maker’s efforts to reduce costs, optimize its product portfolio, and ...